NewsBenzingaRezolute 以每股 3.87 美元定价约 1 亿美元的发行,发行 2200 万股,并附带可按 3.869 美元/预融资认股权证购买最多 380 万股的认股权证 Rezolute 以每股 3.87 美元定价约 1 亿美元的发行,发行 2200 万股,并附带可按 3.869 美元/预融资认股权证购买最多 380 万股的认股权证 Benzinga 2026.11.13 11:23 (GMT+0) Open on Benzinga Other news Salesforce Issues Security Advisory On Third-Party Optimizely Script Incident Affecting Certain Salesforce-Branded Sites; Optimizely Scripts Being Confirmed Disabled FBI Reissues Warning About AI-Powered Cyberattacks on Businesses as Crypto Bettors Dismiss AI Link to FAA Outage SpaceX, Meta and Nebius Stand to Benefit From Nvidia’s ‘Fastest Product Ramp’ Yet: Strategist Shay Boloor Explains Why Binance Plans to Expand into Five Asian Markets Next Year, Focusing on South and Southeast Asia Innate Pharma Reports IPH4502 Phase 1 Data Across 76 Patients: Maximum Tolerated Dose 3.6 Mg/Kg Q3W, Grade 3+ TEAEs In 43.4%, Stomatitis Only Dose-Limiting Toxicity Olema Reports Selective KAT6A Degraders Potently Inhibit Proliferation In Diverse ER+/HER2- Breast Cancer Models, Active In ESR1-Mutant And Wild-Type, Well-Tolerated
Salesforce Issues Security Advisory On Third-Party Optimizely Script Incident Affecting Certain Salesforce-Branded Sites; Optimizely Scripts Being Confirmed Disabled
FBI Reissues Warning About AI-Powered Cyberattacks on Businesses as Crypto Bettors Dismiss AI Link to FAA Outage
SpaceX, Meta and Nebius Stand to Benefit From Nvidia’s ‘Fastest Product Ramp’ Yet: Strategist Shay Boloor Explains Why
Innate Pharma Reports IPH4502 Phase 1 Data Across 76 Patients: Maximum Tolerated Dose 3.6 Mg/Kg Q3W, Grade 3+ TEAEs In 43.4%, Stomatitis Only Dose-Limiting Toxicity
Olema Reports Selective KAT6A Degraders Potently Inhibit Proliferation In Diverse ER+/HER2- Breast Cancer Models, Active In ESR1-Mutant And Wild-Type, Well-Tolerated